Health & Fitness
Health and Fitness
Health and Fitness
Thu, December 17, 2009
Wed, December 16, 2009 Vicor Technologies' Financial Data Now Available via Standard & Poor's Market Access Program
BOCA RATON, FL--(Marketwire - December 16, 2009) - David H. Fater, CEO of Vicor Technologies, Inc. (
Standard & Poor's Market Access Program is an information distribution service that enables subscribing publicly-traded companies to have company data made available to users of Standard & Poor's Advisor Insight, an internet-based research engine used by more than 100,000 investment advisors. Company information made available through Standard & Poor's Market Access Program includes share price, volume, dividends, shares outstanding, company financial position, and earnings. A public version of Standard & Poor's Advisor Insight is available at [ www.advisorinsight.com ].
"Inclusion of Vicor's data in Standard & Poor's Market Access program increases awareness of Vicor among investment advisors and other populations important to building investor awareness of Vicor," stated Mr. Fater. "As such, it is just one of many tools we're employing to ensure widespread awareness of the opportunity Vicor presents for investors, especially in the current healthcare environment where diagnostics that enable inexpensive, accurate, and early diagnosis to avoid the unnecessary costs of advanced disease and inaccurate diagnosis are garnering increased interest," Mr. Fater concluded.
Company data included in Standard & Poor's Market Access Program is also available via S&P's Stock Guide database, which is distributed electronically to virtually all major quote vendors. It is also published in the Daily News section of Standard Corporate Records, a recognized securities manual for secondary trading in up to 38 states under their Blue Sky Laws.
About Vicor Technologies, Inc.
Vicor Technologies is a biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i®). The PD2i® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials to predict future pathological events with a high degree of accuracy in target populations.
Vicor currently has three products employing the PD2i® nonlinear algorithm. The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability; physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research ([ http://www.usaisr.amedd.army.mil/ ]), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of sudden cardiac death.
Vicor anticipates additional applications employing the PD2i® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at [ www.vicortech.com ].
Company information distributed through the Market Access Program is based upon information Standard & Poor's considers to be reliable, but neither Standard & Poor's nor its affiliates warrant its completeness or accuracy, and it should not be relied upon as such. This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument.
The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein.
Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to obtain FDA approval of the PD2i VS™ (Vital Sign) for military and civilian applications and the PD2i CA™(Cardiac Analyzer), our ability to continue to receive financing sufficient to continue operations and complete the critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies, included but not limited to our ASP distribution model for the PD2i Analyzer™; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.
Release 09-25
